The eEF2 kinase coordinates the DNA damage response to cisplatin by supporting p53 activation.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
13 Jul 2024
13 Jul 2024
Historique:
received:
06
04
2023
accepted:
04
07
2024
revised:
27
06
2024
medline:
14
7
2024
pubmed:
14
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K) is a stress-responsive hub that inhibits the translation elongation factor eEF2, and consequently mRNA translation elongation, in response to hypoxia and nutrient deprivation. EEF2K is also involved in the response to DNA damage but its role in response to DNA crosslinks, as induced by cisplatin, is not known. Here we found that eEF2K is critical to mediate the cellular response to cisplatin. We uncovered that eEF2K deficient cells are more resistant to cisplatin treatment. Mechanistically, eEF2K deficiency blunts the activation of the DNA damage response associated ATM and ATR pathways, in turn preventing p53 activation and therefore compromising induction of cisplatin-induced apoptosis. We also report that loss of eEF2K delays the resolution of DNA damage triggered by cisplatin, suggesting that eEF2K contributes to DNA damage repair in response to cisplatin. In support of this, our data shows that eEF2K promotes the expression of the DNA repair protein ERCC1, critical for the repair of cisplatin-caused DNA damage. Finally, using Caenorhabditis elegans as an in vivo model, we find that deletion of efk-1, the worm eEF2K ortholog, mitigates the induction of germ cell death in response to cisplatin. Together, our data highlight that eEF2K represents an evolutionary conserved mediator of the DNA damage response to cisplatin which promotes p53 activation to induce cell death, or alternatively facilitates DNA repair, depending on the extent of DNA damage.
Identifiants
pubmed: 39003251
doi: 10.1038/s41419-024-06891-4
pii: 10.1038/s41419-024-06891-4
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Tumor Suppressor Protein p53
0
Elongation Factor 2 Kinase
EC 2.7.11.20
EEF2K protein, human
EC 2.7.1.17
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
501Informations de copyright
© 2024. The Author(s).
Références
Ryazanov AG, Shestakova EA, Natapov PG. Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation. Nature. 1988;334:170–3.
doi: 10.1038/334170a0
pubmed: 3386756
Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J. 2007;403:217–34.
doi: 10.1042/BJ20070024
pubmed: 17376031
Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013;153:1064–79.
doi: 10.1016/j.cell.2013.04.055
pubmed: 23706743
pmcid: 4395874
Delaidelli A, Leprivier G, Sorensen PH. eEF2K protects MYCN-amplified cells from starvation. Cell Cycle. 2017;16:1633–4.
doi: 10.1080/15384101.2017.1355180
pubmed: 28767324
pmcid: 5602424
Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol. 2006;26:3955–65.
doi: 10.1128/MCB.26.10.3955-3965.2006
pubmed: 16648488
pmcid: 1489005
Moore CE, Mikolajek H, Regufe da Mota S, Wang X, Kenney JW, Werner JM, et al. Elongation Factor 2 Kinase Is Regulated by Proline Hydroxylation and Protects Cells during Hypoxia. Mol Cell Biol. 2015;35:1788–804.
doi: 10.1128/MCB.01457-14
pubmed: 25755286
pmcid: 4405635
Kruiswijk F, Yuniati L, Magliozzi R, Low TY, Lim R, Bolder R, et al. Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress. Sci Signal. 2012;5:ra40.
doi: 10.1126/scisignal.2002718
pubmed: 22669845
Chu HP, Liao Y, Novak JS, Hu Z, Merkin JJ, Shymkiv Y, et al. Germline quality control: eEF2K stands guard to eliminate defective oocytes. Dev Cell. 2014;28:561–72.
doi: 10.1016/j.devcel.2014.01.027
pubmed: 24582807
pmcid: 4712648
Liao Y, Chu HP, Hu Z, Merkin JJ, Chen J, Liu Z, et al. Paradoxical Roles of Elongation Factor-2 Kinase in Stem Cell Survival. J Biol Chem. 2016;291:19545–57.
doi: 10.1074/jbc.M116.724856
pubmed: 27466362
pmcid: 5016690
Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry. 1986;25:3912–5.
doi: 10.1021/bi00361a026
pubmed: 3741840
Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011;11:467–80.
doi: 10.1038/nrc3088
pubmed: 21701511
pmcid: 3560328
Raschle M, Knipscheer P, Enoiu M, Angelov T, Sun J, Griffith JD, et al. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell. 2008;134:969–80.
doi: 10.1016/j.cell.2008.08.030
pubmed: 18805090
pmcid: 2748255
Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63:1311–6.
pubmed: 12649192
Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000;60:1305–13.
doi: 10.1016/S0006-2952(00)00441-X
pubmed: 11008124
Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568–74.
doi: 10.1038/nm852
pubmed: 12692539
Hartley JM, Spanswick VJ, Hartley JA. Measurement of DNA damage in individual cells using the Single Cell Gel Electrophoresis (Comet) assay. Methods Mol Biol. 2011;731:309–20.
doi: 10.1007/978-1-61779-080-5_25
pubmed: 21516417
Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J. 1995;312:163–7.
doi: 10.1042/bj3120163
pubmed: 7492307
pmcid: 1136240
Xie CM, Liu XY, Sham KW, Lai JM, Cheng CH. Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells. Autophagy. 2014;10:1495–508.
doi: 10.4161/auto.29164
pubmed: 24955726
pmcid: 4206530
Chow HM, Cheng A, Song X, Swerdel MR, Hart RP, Herrup K. ATM is activated by ATP depletion and modulates mitochondrial function through NRF1. J Cell Biol. 2019;218:909–28.
doi: 10.1083/jcb.201806197
pubmed: 30642892
pmcid: 6400560
Peng A, Lewellyn AL, Schiemann WP, Maller JL. Repo-man controls a protein phosphatase 1-dependent threshold for DNA damage checkpoint activation. Curr Biol. 2010;20:387–96.
doi: 10.1016/j.cub.2010.01.020
pubmed: 20188555
pmcid: 2860455
Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell. 2006;23:757–64.
doi: 10.1016/j.molcel.2006.07.010
pubmed: 16949371
Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR, et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene. 2004;23:3265–71.
doi: 10.1038/sj.onc.1207494
pubmed: 15064735
Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2007;293:F1282–91.
doi: 10.1152/ajprenal.00230.2007
pubmed: 17670903
Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amst). 2003;2:49–60.
doi: 10.1016/S1568-7864(02)00185-4
pubmed: 12509267
Wang X, Xie J, Proud CG. Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer. Cancers (Basel). 2017;9:1–15.
Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70.
doi: 10.1038/nature03482
pubmed: 15829956
Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–13.
doi: 10.1038/nature03485
pubmed: 15829965
Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–8.
doi: 10.1038/nature08467
pubmed: 19847258
pmcid: 2906700
Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78–94.
doi: 10.1038/s41568-022-00535-5
pubmed: 36471053
Stiernagle T. Maintenance of C. elegans. WormBook. 2006:1–11.
Cecchini MJ, Amiri M, Dick FA. Analysis of cell cycle position in mammalian cells. J Vis Exp. 2012;21:3491.
Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6.
doi: 10.1126/science.1140321
pubmed: 17525332